BIOXYTRAN, INC.
Income Statement
| Line Item | Jun 2018 | Mar 2018 | Dec 2017 | Sep 2017 | Jun 2017 | Mar 2017 | Dec 2016 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $20.3K | $13.3K | $32.2K | $112.0K | $39.5K | $7.4K | $58.2K | $101.1K |
| Cost of Revenue | $8.1K | $15.2K | $39.0K | $31.9K | $19.4K | $13.7K | $22.5K | $38.2K |
| Gross Profit | $12.2K | $-1.9K | $-6.8K | $80.1K | $20.1K | $-6.2K | $35.7K | $62.9K |
| Gross Margin | 60.0% | -14.5% | -21.2% | 71.5% | 50.9% | -83.9% | 61.4% | 62.2% |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $124.9K | $25.7K | $1.3K | $29.3K | $278.5K | $56.4K | $-101.5K | $275.0K |
| Operating Income | $-275 | $-670 | $-86.4K | $50.8K | $-258.5K | $-62.6K | $137.2K | $-212.0K |
| Operating Margin | -1.4% | -5.0% | -268.4% | 45.4% | -654.8% | -842.3% | 235.8% | -209.6% |
| Interest Expense | $3.1K | $2.0K | — | — | $2.0K | $2.0K | $2.0K | $2.0K |
| Pretax Income | $-275 | $-670 | $-86.4K | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-275 | $-670 | $-86.4K | $48.9K | $-260.4K | $-64.6K | $135.3K | $-214.0K |
| Net Margin | -1.4% | -5.0% | -268.4% | 43.7% | -659.8% | -868.6% | 232.4% | -211.6% |
| EPS (Basic) | $0.00 | $0.00 | $0.00 | $0.00 | $-0.01 | $-0.03 | $0.01 | $-0.01 |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $-0.01 | $-0.03 | $0.01 | $-0.01 |
| Shares Outstanding (Basic) | 110.4M | 105.4M | 85.1M | 34.9M | 34.9M | 23.8M | 28.2M | 31.2M |
| Shares Outstanding (Diluted) | 110.4M | 105.4M | 85.1M | 34.9M | 34.9M | 23.8M | 28.2M | 31.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |